In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.

ABSTRACT: Developing a safe and effective antiviral treatment takes a decade, however, when it comes to the coronavirus disease (COVID-19), time is a sensitive matter to slow the spread of the pandemic. Screening approved antiviral drugs against COVID-19 would speed the process of finding therapeutic treatment. The current study examines commercially approved drugs to repurpose them against COVID-19 virus main protease using structure-based in-silico screening. The main protease of the coronavirus is essential in the viral replication and is involved in polyprotein cleavage and immune regulation, making it an effective target when developing the treatment. A Number of approved antiviral drugs were tested against COVID-19 virus using molecular docking analysis by calculating the free natural affinity

SUBMITTER: Khater I 

PROVIDER: S-EPMC8173495 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature